Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT04090034
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Peptide Receptor Radionuclide Therapy — PROCEDURE
    a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs

Study Details

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Key Dates

First listed
Sep 16, 2019
Start date
Mar 28, 2024
Status verified
Mar 2026
Primary completion
Jun 28, 2026
Completion
Jun 28, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Treated w PRRT
    Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.

Primary Outcome Measure

Demographics and other patient data [ Time Frame: 7 years from date of procedure ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Clinical Research Institute at Methodist Health SystemDallasTexas75203
Colette N Ndjom, MS
[email protected]
410-947-4681
Loretta W Bedell, MPH
[email protected]
214-947-4680
Alejandro Mejia, MD (PRINCIPAL_INVESTIGATOR)
Methodist Dallas Medical CenterDallasTexas75203-

Find similar trials in Dallas, TX

Nationwide
Neuroendocrine tumors trialsOncology trials
By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Clinical Research Institute at Methodist Health System· Dallas, TXMethodist Dallas Medical Center· Dallas, TX

Related Studies